AHCYL2

Across TCGA pan-cancer cohorts, AHCYL2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AHCYL2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AHCYL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AHCYL2 expression acts as an unfavorable survival marker.

UCEC, ACC, and ESCA are the cancer types where AHCYL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
ESCA	DFS	Median	II,III,IV	0.221	0.528	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AHCYL2–UCEC (OS)

Open the UCEC breakdown →